Last reviewed · How we verify
ChimeriVax™-JE vaccine
At a glance
| Generic name | ChimeriVax™-JE vaccine |
|---|---|
| Also known as | ChimeriVax™-JE |
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines (PHASE3)
- Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children (PHASE2)
- Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. (PHASE3)
- A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX (PHASE3)
- Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine (PHASE2)
- Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) (PHASE2)
- Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age (PHASE2)
- A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChimeriVax™-JE vaccine CI brief — competitive landscape report
- ChimeriVax™-JE vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI